Compare RYZ & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYZ | ANAB |
|---|---|---|
| Founded | 1842 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2010 | 2015 |
| Metric | RYZ | ANAB |
|---|---|---|
| Price | $27.41 | $46.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $29.00 | ★ $87.25 |
| AVG Volume (30 Days) | 403.7K | ★ 526.1K |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $4,571,300,000.00 | $234,603,000.00 |
| Revenue This Year | $62.92 | $17.97 |
| Revenue Next Year | $1.66 | $36.88 |
| P/E Ratio | $63.64 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $19.34 | $30.27 |
| 52 Week High | $32.00 | $73.30 |
| Indicator | RYZ | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 62.49 | 38.94 |
| Support Level | $26.74 | $44.43 |
| Resistance Level | $29.20 | $51.27 |
| Average True Range (ATR) | 0.91 | 1.70 |
| MACD | 0.26 | 0.12 |
| Stochastic Oscillator | 83.01 | 35.40 |
Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company has one operating and reportable segment, metals service centers. It derives substantially all of its sales from the processing and distribution of met. Geographically, the majority revenue is generated from the United States.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).